VKTX241227C38000
- 3.80
- +0.46+13.77%
Viking Therapeutics Newsroom
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
B.Riley Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $109
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
B.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Viking Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Viking Therapeutics Analyst Ratings
Promising Prospects for Viking Therapeutics' VK2735 in Obesity Treatment: A Buy Rating With $125 Price Target
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Piper Sandler Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $74
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Viking Therapeutics Analyst Ratings
B.Riley Financial Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $109
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Raises Target Price to $164
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)